Cornelis J. A. Punt, MD, PhD | Authors

Cornelis J. A. Punt, MD, PhD, Discussed How CAIRO5 Results of Bevacizumab Plus Triplet Chemo for Unresectable CRC Liver Mets Reinforce Use of the Regimen

August 30, 2022

Cornelis J. A. Punt, MD, PhD, spoke about bevacizumab plus either FOLFOXIRI or FOLFOX/FOLFIRI in patients with unresectable colorectal liver metastases and right-sided or RAS/BRAF-mutant tumors and how these regimens may be used for curative-intent therapy.

Cornelis J. A. Punt, MD, PhD, Reviews Bevacizumab Plus Triplet or Doublet Chemo in Unresectable CRC Liver Metastases

July 31, 2022

Cornelis J. A. Punt, MD, PhD, spoke about the phase 3 CAIRO5 trial of bevacizumab plus either FOLFOXIRI or FOLFOX/FOLFIRI for patients with initially unresectable colorectal liver metastases.